American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC.
J Thorac Oncol
; 16(1): 54-65, 2021 01.
Article
em En
| MEDLINE
| ID: mdl-33011389
ABSTRACT
INTRODUCTION:
The standard-of-care therapy for extensive-stage SCLC has recently changed with the results of two large randomized trials revealing improved survival with the addition of immunotherapy to first-line platinum or etoposide chemotherapy. This has led to a lack of clarity around the role of consolidative thoracic radiation and prophylactic cranial irradiation in the setting of chemoimmunotherapy.METHODS:
The American Radium Society Appropriate Use Criteria are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with the application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for extensive-stage SCLC.RESULTS:
Current evidence supports either prophylactic cranial irradiation or surveillance with magnetic resonance imaging every 3 months for patients without evidence of brain metastases. Patients with brain metastases should receive whole-brain radiation with a recommended dose of 30 Gy in 10 fractions. Consolidative thoracic radiation can be considered in selected cases with the recommended dose ranging from 30 to 54 Gy; this recommendation was driven by expert opinion owing to the limited strength of evidence, as clinical trials addressing this question remain ongoing.CONCLUSIONS:
Radiation therapy remains an integral component in the treatment paradigm for ES-SCLC.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Rádio (Elemento)
/
Carcinoma de Pequenas Células do Pulmão
/
Neoplasias Pulmonares
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article